Seiji Yano

Summary

Affiliation: Kanazawa University
Country: Japan

Publications

  1. doi request reprint The current state of molecularly targeted drugs targeting HGF/Met
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13 1 Takara machi, Kanazawa, Ishikawa 920 0934, Japan
    Jpn J Clin Oncol 44:9-12. 2014
  2. doi request reprint The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
    Takako Sano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Int J Cancer 133:505-13. 2013
  3. doi request reprint Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa
    Cancer Sci 103:1189-94. 2012
  4. doi request reprint Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Cancer Res 68:9479-87. 2008
  5. ncbi request reprint Antiangiogenic therapies for malignant pleural mesothelioma
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University Kanazawa, Ishikawa 920 0934, Japan
    Front Biosci (Landmark Ed) 16:740-8. 2011
  6. doi request reprint Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Takara machi, Kanazawa, Japan
    J Thorac Oncol 6:2011-7. 2011
  7. doi request reprint Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer
    Takayuki Nakagawa
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13 1 Takara machi, Kanazawa, Ishikawa 920 0934, Japan
    Mol Cancer Ther 11:2149-57. 2012
  8. doi request reprint Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells
    Tadaaki Yamada
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Clin Cancer Res 18:3592-602. 2012
  9. doi request reprint Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer
    Lu Zhao
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Cancer Sci 104:1640-6. 2013
  10. doi request reprint Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer
    Ivan S Donev
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Clin Cancer Res 17:2260-9. 2011

Collaborators

Detail Information

Publications31

  1. doi request reprint The current state of molecularly targeted drugs targeting HGF/Met
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13 1 Takara machi, Kanazawa, Ishikawa 920 0934, Japan
    Jpn J Clin Oncol 44:9-12. 2014
    ..This article describes the association relationship between hepatocyte growth factor/Met and cancer and it describes the latest findings regarding inhibitors to target hepatocyte growth factor/Met that are currently being developed. ..
  2. doi request reprint The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
    Takako Sano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Int J Cancer 133:505-13. 2013
    ..These results suggest that BEZ235, even as monotherapy, may be useful in managing HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer...
  3. doi request reprint Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa
    Cancer Sci 103:1189-94. 2012
    ..This review focuses specifically on receptor activation by ligand stimulation and discusses novel therapeutic strategies that are under development for overcoming resistance to molecular targeted drugs in lung cancer...
  4. doi request reprint Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Cancer Res 68:9479-87. 2008
    ..Therefore, inhibition of HGF-MET signaling may be a considerable strategy for more successful treatment with gefitinib...
  5. ncbi request reprint Antiangiogenic therapies for malignant pleural mesothelioma
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University Kanazawa, Ishikawa 920 0934, Japan
    Front Biosci (Landmark Ed) 16:740-8. 2011
    ..In this review, we introduce current status of clinical strategies and novel therapeutic approaches against angiogenesis in MPM...
  6. doi request reprint Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Takara machi, Kanazawa, Japan
    J Thorac Oncol 6:2011-7. 2011
    ....
  7. doi request reprint Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer
    Takayuki Nakagawa
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13 1 Takara machi, Kanazawa, Ishikawa 920 0934, Japan
    Mol Cancer Ther 11:2149-57. 2012
    ..Further evaluations in clinical trials are warranted...
  8. doi request reprint Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells
    Tadaaki Yamada
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Clin Cancer Res 18:3592-602. 2012
    ..We determined whether microenvironmental factors trigger ALK inhibitor resistance in EML4-ALK lung cancer cells...
  9. doi request reprint Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer
    Lu Zhao
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Cancer Sci 104:1640-6. 2013
    ..Thus, MET signaling pathway may be a potential therapeutic target for peritoneal carcinomatosis of gastric cancer, even without MET amplification. ..
  10. doi request reprint Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer
    Ivan S Donev
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Clin Cancer Res 17:2260-9. 2011
    ..The purpose of this study was to determine whether inhibition of PI3K, a downstream molecule of both EGFR and MET, could overcome HGF-mediated EGFR-TKI resistance in EGFR mutant lung cancer cells PC-9 and HCC827...
  11. pmc mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF
    Daisuke Ishikawa
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    PLoS ONE 8:e62104. 2013
    ....
  12. doi request reprint Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer
    Shinji Takeuchi
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan
    Am J Pathol 181:1034-43. 2012
    ..These results indicate the therapeutic rationale of dual targeting of HGF-Met and VEGF-VEGF receptor 2 for overcoming HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer...
  13. doi request reprint Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer
    Wei Wang
    Kanazawa University, Kanazawa, Ishikawa, Japan
    Clin Cancer Res 18:1663-71. 2012
    ..We assayed whether a new Met kinase inhibitor, E7050, which is currently being evaluated in clinical trials, could overcome these three mechanisms of resistance to EGFR-TKIs...
  14. doi request reprint Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
    Wei Wang
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Clin Cancer Res 15:6630-8. 2009
    ..We have therefore assessed the effect of crosstalk between stromal cells and lung cancer cells harboring EGFR mutations on susceptibility to EGFR-TKIs...
  15. doi request reprint Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis
    Hitomi Koizumi
    Division of Medical Oncology, Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    J Thorac Oncol 7:1078-85. 2012
    ..Here, we determined whether inhibition of Hsp90 could overcome HGF-triggered EGFR-TKI resistance in EGFR mutant lung cancer cells...
  16. doi request reprint Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer
    Tadaaki Yamada
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    J Thorac Oncol 7:272-80. 2012
    ..We therefore determined whether HGF could induce resistance to the anti-EGFR antibody (EGFR Ab) cetuximab in lung cancer cells, regardless of EGFR gene status...
  17. doi request reprint Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer
    Tadaaki Yamada
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan
    Clin Cancer Res 16:174-83. 2010
    ..Here, we investigated whether HGF induced resistance to the irreversible EGFR-TKI, CL-387,785, in lung cancer cells (H1975) harboring both L858R activating mutation and T790M secondary mutation in EGFR...
  18. ncbi request reprint [Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective]
    Tadaaki Yamada
    Kanazawa University, Japan
    Gan To Kagaku Ryoho 39:1291-4. 2012
    ..Subsequently, multiple metastatic tumors gradually reduced and clinical benefit was observed for a long time...
  19. doi request reprint EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
    Takayuki Nakagawa
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Cancer Res 73:2428-34. 2013
    ..Together, our results show how HDAC inhibition can epigenetically restore BIM function and death sensitivity of EGFR-TKI in cases of EGFR-mutant NSCLC where resistance to EGFR-TKI is associated with a common BIM polymorphism...
  20. pmc Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network
    Qi Li
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Am J Pathol 179:1483-93. 2011
    ..These findings indicate that MPM instigates tumor-associated fibroblasts, promoting tumor progression via a malignant cytokine network. Regulation of this cytokine network may be therapeutically useful for controlling MPM...
  21. ncbi request reprint [PI3K inhibitor]
    Seiji Yano
    Division of Medical Oncology Cancer Research Institute, Kanazawa University, Japan
    Gan To Kagaku Ryoho 38:23-6. 2011
    ..Therefore, PI3K is thought to be an ideal therapeutic target. A large number of PI3K inhibitors are being developed and evaluated in clinical trials...
  22. pmc Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors
    Shigeki Nanjo
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    PLoS ONE 8:e84700. 2013
    ..We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generation EGFR-TKIs to overcome resistance to first-generation EGFR-TKIs...
  23. doi request reprint The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer
    Kazuo Yasumoto
    Divisions of Surgical Oncology and Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Clin Cancer Res 17:3619-30. 2011
    ..Here, we investigated whether epidermal growth factor receptor (EGFR) ligands are also involved in the development of peritoneal carcinomatosis from gastric cancer...
  24. doi request reprint Synchronous triple cancers of the pancreas, stomach, and cecum treated with s-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency
    Koushiro Ohtsubo
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University Kanazawa, Japan
    JOP 14:515-20. 2013
    ..Pancreatic cancer is frequently complicated by malignancies in other organs. However, synchronous triple cancers including pancreatic cancer have been seldom reported in the English language literature...
  25. doi request reprint Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells
    Tadaaki Yamada
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan
    Cancer Sci 102:2157-63. 2011
    ..These findings suggest that humanized anti-GM2 antibodies could be therapeutically useful for controlling multiple organ metastases of GM2-expressing SCLC...
  26. ncbi request reprint Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy
    Koushiro Ohtsubo
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Intern Med 48:1651-6. 2009
    ..Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically...
  27. doi request reprint Endoscopic findings of upper gastrointestinal lesions in patients with pancreatic cancer
    Koushiro Ohtsubo
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    JOP 13:420-6. 2012
    ..However, there have been few endoscopic studies in pancreatic cancer patients. We retrospectively investigated the upper gastrointestinal lesions in patients with pancreatic cancer who underwent upper gastrointestinal endoscopy...
  28. doi request reprint Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma
    Makio Moriya
    Department of General and Cardiothoracic Surgery, Kanazawa University, Kanazawa, Japan
    Oncol Rep 31:1109-15. 2014
    ..These results suggest that temsirolimus has activity against MPM cells by inhibition of cell proliferation and angiogenesis, and may be beneficial for a subset of MPM patients with high mTOR expression. ..
  29. doi request reprint Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib
    Tadaaki Yamada
    Cancer Center, Kanazawa University, 13 1 Takara machi, Kanazawa 920 8641, Japan
    Int J Clin Oncol 15:638-41. 2010
    ..Care should be taken with pulmonary hemorrhage in the use of anti-angiogenesis agents in not only squamous cell lung cancer, but also metastatic lung tumors...
  30. doi request reprint Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis
    Tadaaki Yamada
    Kanazawa University Hospital Cancer Center, Kanazawa, Japan
    Int J Clin Oncol 14:468-72. 2009
    ..Because this clinical condition is extremely rare, a gold standard treatment has yet to be established...
  31. doi request reprint The role of percutaneous needle biopsy in differentiation of renal tumors
    Kouji Izumi
    Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan
    Jpn J Clin Oncol 40:1081-6. 2010
    ..In this study, we examined the background, accuracy, adverse events and patient prognosis associated with such biopsies...